Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) CEO Seth Lederman presents to investors at Proactive's One2One Virtual Event.
Tonix is a New York-based, clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions.
Price: 0.6112 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE
Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. (NASDAQ: TNXP) CEO Dr. Seth Lederman tells Proactive why the clinical-stage biopharmaceutical company had decided to stop enrollment in its Phase 3 RALLY study of TNX-102 SL to treat fibromyalgia. In addition, Dr. Lederman discussed the...
Retail & consumer
Prev article
